Glucomannan
A natural appetite suppressant and fiber supplement used for weight loss and Digestive regularity.
Glucomannan is a highly viscous dietary fiber from konjac root studied for its potential role in weight management. It may influence satiety and metabolic markers through gut microbiome modulation and delayed gastric emptying.
Quick answer
What it is: Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Amorphophallus konjac).
May support:Obesity
Evidence:Evidence · Grade B
Evidence Summary
Evidence for glucomannan in obesity management is rooted in its physical properties as a soluble fiber. Research into prebiotics highlights their role in inducing beneficial changes in gut microbiota composition, which may improve glucose metabolism and energy regulation in metabolically compromised individuals.
Last reviewed · Jun 2026
Have you tried Glucomannan?
Vote in 5 seconds. Add details if you want.
Your experience for Obesity:
Commonly Combined With
Other remedies frequently used alongside this one — from curated relationships, community reports, and shared protocols.
Community signal breakdown
Where this remedy is being discussed across the web and community.
People Like Me insights
As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Community Discussions
What people say about Glucomannan
Latest News
Latest news on Glucomannan
Health Videos
Health videos on Glucomannan
Why It Works
How it works in more detail
How to use
Always consult a qualified clinician.Editorial guidance
- oral medications (may reduce absorption)
- difficulty swallowing
- esophageal obstruction
- gastrointestinal blockage
Community tips
No community tips yet — be the first to share what worked for you.
Suggested dosage
General guidance — discuss specifics with a clinician.
Active medicinal compounds
Traditional use
Safety
Safety warnings
Avoid if
- difficulty swallowing
- esophageal obstruction
- gastrointestinal blockage
Medication interactions
- oral medications (may reduce absorption)
Reported side effects
- bloating
- flatulence
- abdominal discomfort
- diarrhea
- constipation (if not enough water is consumed)
General guidance — discuss specifics with a clinician.
Evidence ecosystem
Scientific literature, clinical guidance, government sources, ongoing research, traditional use, and lived experience — grouped by source type and quality.
Overall grade (B)
Evidence for glucomannan in obesity management is rooted in its physical properties as a soluble fiber. Research into prebiotics highlights their role in inducing beneficial changes in gut microbiota composition, which may improve glucose metabolism and energy regulation in metabolically compromised individuals.
Filter by source type
Randomized Human Trials(1)
Controlled human studies with random assignment.
Beteri B, Barone M, Turroni S, Brigidi P, Tzortzis G, Vulevic J · Nutrients · 2024
The complex interactions between intestinal microbiota and metabolic disorders are well-documented, with implications for glucose metabolism, energy expenditure, and intestinal permeability. Prebiotics induce beneficial changes in gut microbiota composition in prediabetes, while postbiotics can enhance gut barrier function, complementing each other to improve glucose metabolism and insulin sensitivity. This study investigated the effects of a 12-week dietary fibre (DF) supplement on gut health, metabolic function, and diet. The supplement contained konjac glucomannan (KGM), galacto-oligosaccharides (GOSs), and exopolysaccharides (EPSs) from Bifidobacterium breve. In a randomised, double-blind, placebo-controlled, parallel-group clinical trial, 53 prediabetic volunteers were randomly assigned to either a daily DF supplement (YMETA) or a placebo (cellulose microcrystalline) for 12 weeks, followed by a 4-week follow-up. Measurements included gut microbiota composition, glycated haemoglobi
Randomized TrialPubMedHigh Quality
Animal Studies(1)
Preclinical animal research — not a substitute for human evidence.
Tian Y, Xu J, Li Y, Zhao R, Du S, Lv C · Gastroenterology · 2019 · n=82
Levels of microRNA 31 (MIR31) are increased in intestinal tissues from patients with inflammatory bowel diseases and colitis-associated neoplasias. We investigated the effects of this microRNA on intestinal inflammation by studying mice with colitis. We obtained colon biopsy samples from 82 patients with ulcerative colitis (UC), 79 patients with Crohn's disease (CD), and 34 healthy individuals (controls) at Shanghai Tenth People's Hospital. MIR31- knockout mice and mice with conditional disruption of Mir31 specifically in the intestinal epithelium (MIR31 conditional knockouts) were given dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS) to induce colitis. We performed chromatin immunoprecipitation and luciferase assays to study proteins that regulate expression of MIR31, including STAT3 and p65, in LOVO colorectal cancer cells and organoids derived from mouse colon cells. Partially hydrolyzed alpha-lactalbumin was used to generate peptosome nanoparticles, and
Animal StudyPubMedLow Quality
Limitations: Many studies on glucomannan and gut health involve small sample sizes or animal models, which may not translate directly to human weight loss outcomes. Preclinical data regarding intestinal inflammatory pathways and microRNA signaling often utilize controlled environments that do not account for the complexity of human dietary habits.
This page is educational. Statements use phrases like "may support" and "has been studied for"because no remedy here is approved to cure, treat, or reverse any condition. Discussion happens on the ailment pages — community statistics here are derived from those reports. Always consult a qualified clinician.
Tried Glucomannan?
Help others see what actually works.
Tried Glucomannan?
Real-world results help others choose what's worth trying.